Experts Discuss Their Current Approach to Treating MF

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Find latest Myelofibrosis (MF) videos · 100+ videos

Playback speed

10 seconds

Experts Discuss Their Current Approach to Treating MF

By MyCancerHaven FEATURING Ravi Vij, Abdulraheem Yacoub

129 views

August 30, 2024

Comments 0

Importance of Early Management of Patients with Myelofibrosis (MF)

Feat. P. Bose, R. Rampal

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

2025 Breast Cancer Highlights from International Medical Meetings: 5…

Thu, Mar 6, 2025

Total Health

2025 West Oncology Conference

Sat, Feb 8, 2025

New

ASH 2024 Summary: MPN Highlights and Clinical Implications

2024 ASH Annual Meeting Insights Hub

D. Tremblay

287 views

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Indy Hematology Review

A. Tefferi

1.5K views

Current Approaches in the Treatment of Myeloproliferative Neoplasms

Indy Hematology Review

A. Tefferi

1.4K views

ESMO 2024 Summary: Highlights in Heme Malignancies

2024 ESMO Annual Meeting Insights Hub

M. Gomes da Silva

487 views

Myeloid Malignancies: Hot Topics in 2024

Yale Cancer Center

N. Podoltsev

301 views

New

ASH 2024 Summary: Pegylated Interferon in MPN - The Who, Why, and How

2024 ASH Annual Meeting Insights Hub

J. Kiladjian

134 views

Allele Burden in MPN: Practical Considerations

16th International Congress on Myeloproliferative Neoplasms

R. Rampal

155 views

07:44

Incyte

Optimizing the Management of Patients with Polycythemia Vera (PV)

Feat. P. Bose, R. Rampal

16:51

Incyte

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Feat. C. Harrison

Current and Future Treatment Landscape of Myelofibrosis

XV Eurasian Hematology-Oncology Congress - EHOC 2024

R. Komrokji

177 views

Novel Agents for MPNs in 2024

16th International Congress on Myeloproliferative Neoplasms

N. Pemmaraju

121 views

New

ASH 2024 Insights: Updated Ph3 MANIFEST-2 Results - Pelabresib + Rux…

2024 ASH Annual Meeting Insights Hub

J. Mascarenhas

74 views

Selection of JAK1/2 Inhibitors for Primary Myelofibrosis

16th International Congress on Myeloproliferative Neoplasms

A. Gerds

89 views

16:26

Incyte

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

Feat. C. Harrison

SIMPLIFY-2 Trial: Momelotinib Vs. Continued Ruxolitinib or Best Avai…

Cleveland Clinic Taussig Cancer Institute

A. Gerds

307 views

Experts Discuss How They Choose 2L Therapy in MF

MyCancerHaven

R. Vij, P. Bose

164 views

Management of MF After Ruxolitinib Failure

Vanderbilt University Medical Center (VUMC)

A. Kishtagari

203 views

New

ASH 2024 Summary: Survival Outcomes in Patients With MF & New or Wor…

2024 ASH Annual Meeting Insights Hub

A. Kuykendall

51 views

Current Management of Accelerated/Blast-Phase MPNs

UChicago Medicine

A. Patel

76 views

Approach to Selecting Treatment for Myelofibrosis in 2024

GRACE

A. Srisuwananukorn

46 views

AUTOPLAY

Login

Login

Join VuMedi

Experts Discuss Their Current Approach to Treating MF

Importance of Early Management of Patients with Myelofibrosis (MF)

A proven CD123 targeted therapy for BPDCN

Related Videos

2025 Breast Cancer Highlights from International Medical Meetings: 5…

2025 West Oncology Conference

ASH 2024 Summary: MPN Highlights and Clinical Implications

Evaluation, Diagnosis, Prognostication, and Emerging Therapies for M…

Current Approaches in the Treatment of Myeloproliferative Neoplasms

ESMO 2024 Summary: Highlights in Heme Malignancies

Myeloid Malignancies: Hot Topics in 2024

ASH 2024 Summary: Pegylated Interferon in MPN - The Who, Why, and How

Allele Burden in MPN: Practical Considerations

Optimizing the Management of Patients with Polycythemia Vera (PV)

Effects of PV Treatment on White Blood Cell Count and Thrombotic Risk

Current and Future Treatment Landscape of Myelofibrosis

Novel Agents for MPNs in 2024

ASH 2024 Insights: Updated Ph3 MANIFEST-2 Results - Pelabresib + Rux…

Selection of JAK1/2 Inhibitors for Primary Myelofibrosis

Effects of a Treatment Option on Hematocrit Control and Spleen Volum…

SIMPLIFY-2 Trial: Momelotinib Vs. Continued Ruxolitinib or Best Avai…

Experts Discuss How They Choose 2L Therapy in MF

Management of MF After Ruxolitinib Failure

ASH 2024 Summary: Survival Outcomes in Patients With MF & New or Wor…

Current Management of Accelerated/Blast-Phase MPNs

Approach to Selecting Treatment for Myelofibrosis in 2024